Prognostic Significance of Volume-Based FDG PET/CT Parameters in Patients with Locally Advanced Pancreatic Cancer Treated with Chemoradiation Therapy by 媛뺣쾭�뱾 et al.
Yonsei Med J   http://www.eymj.org   Volume 55   Number 6   November 20141498
Prognostic Significance of  Volume-Based FDG PET/CT 
Parameters in Patients with Locally Advanced Pancreatic Cancer 
Treated with Chemoradiation Therapy
Hye Jin Choi,1 Jeong Won Lee,2 Beodeul Kang,1 Si Young Song,3 Jong Doo Lee,2 and Jae-Hoon Lee2
1Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul;
Departments of 2Nuclear Medicine and 3Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Received: February 19, 2014
Revised: June 9, 2014
Accepted: June 17, 2014
Corresponding author: Dr. Jae-Hoon Lee, 
Department of Nuclear Medicine, 
Yonsei University College of Medicine, 
50-1 Yonsei-ro, Seodaemun-gu, 
Seoul 120-752, Korea.
Tel: 82-2-2228-2350, Fax: 82-2-312-0578
E-mail: docnuke@yuhs.ac
∙ The authors have no financial conflicts of 
interest.
© Copyright:
Yonsei University College of Medicine 2014
This is an Open Access article distributed under the 
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/ 
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any 
medium, provided the original work is properly cited.
Purpose: We investigated the prognostic role of volume-based parameters measured 
on 18F-fluorodeoxyglucose (FDG) positron emission tomography-computed tomog-
raphy (PET/CT) scans in patients with locally advanced pancreatic cancer (LAPC) 
treated with chemoradiation therapy (CRT). Materials and Methods: We enrolled 
60 patients with LAPC who underwent FDG PET/CT before CRT. Maximum stan-
dardized uptake value (SUVmax), metabolic tumor volume (MTV), and total lesion 
glycolysis (TLG) of primary pancreatic cancers were measured on FDG PET/CT 
scans. Treatment response was evaluated according to the Response Evaluation Cri-
teria in Solid Tumors. Survival analysis was performed using the Kaplan-Meier 
method, and Cox proportional hazard models were used to determine independent 
prognostic factors. Results: The progression-free survival (PFS), locoregional pro-
gression-free survival (LRFPS), and overall survival (OS) for this population were 
6.2, 10.9, and 13.2 months, respectively. The overall treatment response rate was 
16.7% at 4 weeks after CRT, and the disease control rate (DCR) was 80.0%. DCR 
was significantly higher in patients with low SUVmax, MTV, or TLG, and showed 
strong correlation with longer survival times. On univariate analysis, MTV and TLG 
were significant prognostic factors for PFS, LRPFS, and OS, together with pre-CRT 
and post-CRT CA19-9 levels. Multivariate analyses demonstrated that MTV togeth-
er with the pre-CRT CA19-9 level were independent prognostic factors for PFS, LR-
PFS, and OS, as was TLG for LRPFS and OS. Conclusion: MTV and the pre-CRT 
CA19-9 level provided independent prognostic information in patients with LAPC 
treated with CRT. Volume-based PET/CT parameters may be useful in identifying 
which subgroup of patients would benefit from radiation therapy as a part of CRT.
Key Words:   Locally advanced pancreatic cancer, FDG, PET, metabolic tumor 
volume, prognosis
INTRODUCTION
Pancreatic cancer is one of the most lethal cancers. According to a recent report, 
about 15% of patients with pancreatic cancer survived 1 year after diagnosis, and 
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part of a staging work-up prior to treatment at our institu-
tion from January 2007 to December 2010. Patients with a 
diagnosis of stage III biopsy-confirmed ductal adenocarci-
noma, who were initially deemed surgically unresectable 
upon staging work-up and who received CRT, were includ-
ed in this study. Sixty patients met the inclusion criteria. 
Baseline patient and tumor characteristics were reviewed, in-
cluding age, gender, Eastern Cooperative Oncology Group 
(ECOG) performance status, history of diabetes mellitus, 
tumor diameter (mm), tumor location, T stage, nodal status, 
and non-obstructive pre-CRT and post-CRT CA19-9 levels. 
The Institutional Review Board of our university approved 
this retrospective study, and the requirement to obtain in-
formed consent was waived.
Acquisition and analysis of FDG PET/CT scans
All FDG PET/CT scans were performed using a dedicated 
PET/CT scanner (Discovery STe, GE Healthcare, Milwau-
kee, WI, USA or Biograph TruePoint 40, Siemens Medical 
Systems, CTI, Knoxville, TN, USA). All patients fasted for 
at least 6 h prior to the PET/CT scan. Median blood glucose 
level was 100 mg/dL with a range of 72‒210 mg/dL. A dose 
of approximately 5.5 MBq/kg of FDG was intravenously 
injected 60 min before imaging. After the initial low-dose 
CT (Discovery STe: 30 mA, 130 kVp; Biograph TruePoint: 
36 mA, 120 kVp), the PET scan extending from the neck to 
the proximal thighs with an acquisition time of 3 min per 
bed position in 3-D mode was performed. The PET scans 
were reconstructed using ordered subset expectation maxi-
mization with attenuation correction. 
Volume-based assessment of the primary pancreatic can-
cer lesion was performed using the volume viewer software 
on a GE Medical Systems Advantage Workstation 4.5. Each 
tumor was examined with a spherical-shaped volume of in-
terest (VOI) that included the entire lesion in the axial, sag-
ittal, and coronal planes. The maximum SUV (SUVmax) of 
the VOI was calculated as (decay-corrected activity/tissue 
volume)/(injected dose/body weight). Once the threshold 
for volumetric analysis was assigned, the software automati-
cally calculated MTV and mean SUV of the VOI from PET 
data by grouping all spatially connected voxels equal to or 
above the threshold. In this study, MTV was defined as total 
tumor volume with SUV ≥2.5, and TLG was calculated as 
(mean SUV)×MTV.
Treatment delivery
All 60 patients who underwent CRT received gemcitabine-
fewer than 5% survived 5 years.1 Only 20% of patients 
with pancreatic cancer have resectable tumors at the time of 
presentation, with a long-term survival rate of approximate-
ly 20%.2,3 A much higher percentage (40% to 45%) of pa-
tients present with metastatic disease and have a median 
survival of only 3‒6 months.4,5 
Patients with locally advanced pancreatic cancer (LAPC) 
are an intermediate favorable prognostic group and are as-
sociated with a median survival of 6‒10 months.4,6 Treat-
ment for LAPC has evolved to consist of chemotherapy 
alone or in combination with radiotherapy. Although 
chemoradiation therapy (CRT) remains a treatment option, 
only a small number of randomized clinical trials have re-
ported improved survival outcomes,7-9 and many have ar-
gued the value of radiation therapy (RT) for the subset of 
patients with LAPC due to the high rate of distant metasta-
sis and subsequent poor survival outcomes even after suc-
cessful local control.10
18F-fluorodeoxyglucose (FDG) positron emission tomog-
raphy-computed tomography (PET/CT) is now widely used 
to assess many different types of malignancy, and several 
studies have demonstrated an important role of FDG PET/
CT in staging, detecting postoperative recurrence, and eval-
uating treatment response in patients with pancreatic can-
cer.11,12 Other studies have shown that the standardized up-
take value (SUV) of primary pancreatic cancer lesions 
measured on pretreatment FDG PET/CT scans can help to 
predict survival outcomes in patients with pancreatic can-
cer.12-16 Recently, PET/CT-based volumetric imaging param-
eters, including metabolic tumor volume (MTV) and total 
lesion glycolysis (TLG), have also been shown to be useful 
prognostic indicators for various neoplasms.17-19 However, 
few studies have evaluated volumetric parameters as prog-
nostic factors in patients with LAPC.20 Moreover, while in-
vestigators have established prognostic factors for pancreat-
ic cancer, data regarding LAPC are limited. The objective 
of this study was to investigate the prognostic significance 
of volumetric parameters measured on pretreatment FDG 
PET/CT scans for predicting treatment outcomes in patients 
with LAPC treated with CRT.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of all pan-
creatic cancer patients who underwent FDG PET/CT as 
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the first day of treatment and the date of death or last visit. 
For statistical analyses, all variables for survival were 
grouped into two categories according to specific cutoff 
values. The optimal cutoff values were determined using 
receiver-operating characteristic (ROC) curve analysis. The 
significance of the predictive value of each variable was 
evaluated using log-rank tests for univariate analysis and 
Cox proportional hazards regression tests for multivariate 
analysis. Multicollinearity between MTV and TLG was 
evaluated by calculating the Spearman rank correlation co-
efficient before multivariate analysis. Statistical analyses 
were performed using SPSS 20.0 for Windows (SPSS Inc., 
Chicago, IL, USA). Results with p-values <0.05 were con-
sidered statistically significant.
 
RESULTS
 
Patient characteristics
Table 1 summarizes the pretreatment characteristics of all 60 
patients enrolled in the study according to disease status at 
the 1-year follow up. The median PFS was 6.2 months [95% 
confidence interval (CI): 3.8‒8.6 months] and the overall 
1-year progression-free survival rate was 68%. Distant re-
lapse (n=34; 82.9%) was the main cause of initial treatment 
failure, 31 instances of which were isolated (75.6%) and 3 
(7.3%) that were concomitant with locoregional progression. 
Local treatment failure without concomitant distant metasta-
sis was observed in 8 patients (19.5%), 6 (75%) of whom 
eventually had relapse with distant metastasis. Sites of distant 
metastasis included the liver (n=17), peritoneum (n=9), mul-
tiple organs (n=7), and lungs (n=1). There was no significant 
relationship between the pattern of initial disease progression 
(distant versus local) and PET/CT parameters (SUVmax, 
MTV, and TLG). In comparing patients with and without 
disease progression, SUVmax, MTV, and TLG were signifi-
cantly different between these two groups (p<0.05, all) while 
the other demographic and clinical characteristics did not 
show statistical significance. From the ROC analyses, the op-
timal cut-off values for SUVmax, MTV, and TLG were set at 
6.5, 10.0 cm3, and 45.0 g, respectively. Cut-off values for the 
pre-CRT CA19-9 level, post-CRT CA19-9 level, and decline 
in the CA19-9 levels after CRT were also defined as 646 U/
mL, 144 U/mL, and 87.8%, respectively.
Tumor response assessment
Overall treatment response was 16.7% at the 4-week follow 
based chemotherapy. Only gemcitabine (1000 mg/m2 on 
days 1, 8, 15, 29, and 36) was administered to most patients. 
Cisplatin (70 mg/m2 on days 1 and 29) or capecitabine (total 
daily dose of 2000 mg/m2 for days 1‒14 and 21‒35) was ad-
ditionally administered to some patients depending on the 
preference of the responsible physicians and the general 
condition of the patient. Chemotherapy was withheld until 
the resolution of any grade 3 or 4 non-hematologic toxicity. 
Patients also received conformal radiotherapy or tomo-
therapy as a part of CRT. According to the standard CRT 
protocol, patients received involved-field irradiation con-
sisting of the gross tumor volume (GTV) with a liberal 
margin (2 cm). If significant lymphadenopathy was noted 
on the pre-treatment scans, radiotherapy of the specified 
lymph node areas was also performed. A median total dose 
of 50.4 Gy with a range of 45.0‒58.4 Gy was applied with 
daily fractions of 1.8 Gy for 5 days per week using a 10 
MV linear accelerator. After CRT, patients received mainte-
nance gemcitabine chemotherapy (1000 mg/m2 on days 1, 
8, and 15, every 4 weeks) until disease progression or unac-
ceptable toxicities occurred.
Response evaluation
All 60 enrolled patients had clinical follow-ups that includ-
ed diagnostic imaging studies and blood tests. Tumor re-
sponse was assessed according to the Response Evaluation 
Criteria in Solid Tumors on contrast-enhanced CT scans ob-
tained at 4 weeks after completion of CRT. Disease control 
status, defined as complete response, partial response, or 
stable disease, was also evaluated at each time point. 
Data analysis
All 60 patients were assessed and grouped according to 
whether they had experienced progression of disease at the 
1-year follow up. The SUVmax, MTV, and TLG on FDG 
PET/CT scans, as well other tumor factors, were compared 
between the 2 subgroups using Mann-Whitney U tests, chi-
squared tests, t-tests, and Fisher’s exact tests. Survival curves 
were estimated using the Kaplan-Meier method to calculate 
the cumulative locoregional progression-free survival (LR-
PFS), progression-free survival (PFS), and overall survival 
(OS). LRPFS was defined as survival without local or re-
gional treatment failure, calculated as the time between the 
first day of treatment and the date of local or regional fail-
ure, death, or last visit. The PFS was calculated as the time 
between the first day of treatment and any type of disease 
progression, while the OS was defined as the time between 
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sults between the responder and non-responder groups. 
However, the DCR was significantly higher in patients 
whose tumors had lower SUVmax, MTV, or TLG values 
than those in the other group, while none of the CA19-9 pa-
rameters showed statistical differences. These results are 
summarized in Table 2.
up after CRT, and the disease control rate (DCR) was 80%. 
To assess the predictive value of the PET/CT parameters 
and CA19-9 levels, we classified patients into 2 groups, 
higher and lower, based on the cut-off values obtained from 
the ROC analyses described above. There were no signifi-
cant statistical differences in the PET/CT and CA19-9 re-
Table 1. Patient Characteristics According to Disease Progression at the 1-Year Follow-Up
Characteristics
Total 
(n=60)
Disease progression 
(n=41)
No disease progression 
(n=19)
p value
Sex (M:F) 34:26 23:18 11:8 0.896
Age (yrs), median (range) 64.7 (39.3–87.7) 65.5 (39.3–77.8) 63.9 (50.8–87.7) 0.927
DM, n (%) 21 15 (71.4) 6 (28.6) 0.705
Tumor location, n (%) 0.875
    Head 26 17 (65.4) 9 (34.6)
    Body 26 19 (73.1) 7 (26.9)
    Tail   2   1 (50.0) 1 (50.0)
    Overlapping   6   4 (66.7) 2 (33.3)
Size (cm), mean±SD 4.1±1.0 3.8±0.9 4.2±1.0 0.199
ECOG performance status, n (%) 0.303
    0 18 14 (77.8)   4 (22.2)
    1 42 27 (64.3) 15 (35.7)
LN metastasis, n (%) 0.672
    Yes 18 13 (72.2)   5 (27.8)
    No 42 28 (66.7) 14 (33.3)
CA19-9 (U/mL), median (range)
    Pre-CRT 149.5 (0.1–>20000.0)   147.0 (0.1–>20000.0) 152.0 (0.1–1610.0) 0.369
    Post-CRT   80.4 (0.1–>20000.0)     83.8 (0.1–>20000.0)   63.5 (0.1–1070.0) 0.323
    Decline (%)*   30.0 (-16.8 to 95.2)     30.0 (-16.8 to 95.2)   24.0 (-7.5 to 87.7) 0.973
SUVmax, median (range)   5.90 (2.80–30.10)     6.40 (3.30–30.10)   5.20 (2.80–11.53) 0.037
MTV, median (range) 21.47 (0.31–132.00)   28.66 (4.00–132.00) 10.09 (0.31–65.13) 0.012
TLG, median (range) 69.23 (0.82–567.60) 113.95 (11.20–567.60) 29.49 (0.82–332.16) 0.011
DM, diabetes mellitus; ECOG, Eastern Cooperative Oncology Group; LN, lymph node; SUVmax, maximum standardized uptake value; MTV, metabolic tu-
mor volume; TLG, total lesion glycolysis; CRT, chemoradiation therapy.
*Values below 0.0 indicate increase in CA19-9 level after CRT.
Table 2. Treatment Response and Disease Control Rate According to the PET/CT Parameters
Responder Non-responder Tumor 
response rate
Odds ratio* 
(95% CI)
p value
Disease 
control rate
Odds ratio 
(95% CI)
p value
CR PR SD PD
SUVmax, n 1.000 0.005
    ≤6.5 0   6 29   3 15.8% 0.8 (0.2–3.4)   92.1% 8.1 (1.9–34.6)
    >6.5 0   4   9   9 18.2%   59.1%
MTV, n 0.426 0.027
    ≤10.0 cm3 0   1 14   0   6.7% 0.3 (0.1–2.4) 100.0% - 
    >10.0 cm3 0   9 24 12 20.0%   73.3%
TLG, n 0.727 0.020
    ≤45.0 g 0   3 19   1 13.0% 0.6 (0.2–2.8)   95.7% 9.4 (1.1–78.9)
    >45.0 g 0   7 19 11 18.9%   70.3%
Total 0 10 38 12 16.7%   80.0%
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; SUVmax, maximum standardized uptake value; MTV, metabolic 
tumor volume; TLG, total lesion glycolysis; PET/CT, positron emission tomography-computed tomography; CI, confidence interval.
*Assessed using the 2-sided Fisher’s exact test or the χ2 test.
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Among the significant prognostic variables found by uni-
variate analysis, only those variables that could be assessed 
before treatment were included in the multivariate analysis 
(i.e., SUVmax, MTV, TLG, and the pre-CRT CA19-9 lev-
el). As TLG is calculated by multiplying the mean SUV 
and the MTV, there was a significant correlation between 
the MTV and TLG (r=0.946, p<0.0001). Therefore, MTV 
and TLG were assessed separately. On the multivariate 
analysis, the pre-CRT CA19-9 level and MTV were identi-
fied as independent prognostic factors for PFS, LRPFS, and 
OS (p<0.05, all) (Table 4), while TLG remained statistical-
ly significant for both LRPFS (p=0.008) and OS (p=0.019) 
(Table 5). 
DISCUSSION
To date, few prognostic factors from heterogeneous study 
populations have been identified for LAPC. Bjerregaard, et 
al.21 reported that good performance status with small tu-
mors was significantly associated with favorable prognosis. 
In a multi-center study including patients with LAPC and 
metastatic pancreatic cancer, the pretreatment CA19-9 level 
Survival analysis and prognostic factors
At a median follow up of 13 months (range, 3‒67 months), 
58 out of the 60 evaluated patients (96.7%) had died. One 
patient was alive without disease progression, and the other 
remaining patient was also alive but had liver metastasis 
and peritoneal carcinomatosis. Both patients had consis-
tently lower SUVmax, MTV, and TLG and lower pre-CRT 
and post-CRT CA19-9 levels, which declined significantly 
after CRT. During follow-up, 41 patients (68.3%) experi-
enced some degree of treatment failure. The median dura-
tions of PFS, LRPFS, and OS were 6.2 months (95% CI: 
3.8‒8.6 months), 10.9 months (95% CI: 8.1‒13.7 months), 
and 13.2 months (95% CI: 11.9‒14.5 months), respectively. 
Comparison of survival data using the log-rank test showed 
that MTV and TLG were significant prognostic indicators 
for PFS, LRPFS, and OS (Figs. 1 and 2), as was SUVmax 
for PFS and LRPFS. Through univariate analysis, pre-CRT 
and post-CRT CA19-9 levels were found to have prognos-
tic significance for PFS, LRPFS, and OS. In addition, dis-
ease progression at 4 weeks after treatment was an adverse 
prognostic factor in terms of PFS, LRPFS, and OS. Median 
survival times and corresponding results of univariate anal-
ysis are shown in Table 3. 
Fig. 1. (A) Cumulative progression-free survival, (B) locoregional progression-free survival, and (C) overall survival according to the metabolic tumor volume 
(MTV) of pancreatic cancer lesions.
Fig. 2. (A) Cumulative progression-free survival, (B) locoregional progression-free survival, and (C) overall survival according to the total lesion glycolysis 
(TLG) of pancreatic cancer lesions.
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dependent prognostic factor for poor survival in patients 
with LAPC who were treated with CRT, while a decline in 
the CA19-9 level was not. The post-CRT CA19-9 level did 
have statistical significance upon univariate analysis; howev-
er in the present study, it was excluded from multivariate 
analysis due to our focus on prognostic factors that can be as-
(<1000 U/mL) as well as a CA19-9 decline of >25% after 
treatment were strongly correlated with longer time-to-pro-
gression and OS.22 A decrease in the CA19-9 level (>90%) 
was also an independent predictor of improved median sur-
vival in a study performed by Yang, et al.23 Our analysis indi-
cated that a pre-CRT CA19-9 level of >646 U/mL was an in-
Table 3. Univariate Analysis of Prognostic Factors for Survival Outcomes
PFS LRPFS OS
Median* p value Median p value Median p value
Sex 0.510 0.242 0.204
    Women 5.8   8.8 13.3
    Men 6.6 11.8 13.0
Age (yrs) 0.794 0.831 0.420
    >65 6.0   9.5   9.5
    ≤65 5.8 12.1 13.6
Presence of DM 0.626 0.626 0.725
    Yes 5.8 12.2 13.2
    No 6.3 10.0 12.1
ECOG performance status 0.504 0.257 0.386
    1 6.2 12.1 13.2
    0 3.9   7.3   8.3
LN metastasis 0.760 0.337 0.832
    Yes 5.1   9.5 11.8
    No 6.2 10.7 13.6
Tumor location 0.566 0.161 0.526
    Head 6.2 12.2 13.2
    Body/tail 3.9   7.8 10.7
SUVmax 0.015 0.028 0.172
    >6.5 3.9   7.8   9.6
    ≤6.5 8.5 13.1 13.3
MTV 0.001 0.002 0.008
    >10.0 cm3 4.7   9.1 11.8
    ≤10.0 cm3 16.0 20.8 20.8
TLG 0.017 0.003 0.007
    >45.0 g 4.2   8.3   9.6
    ≤45.0 g 9.8 14.6 16.0
Pre-CRT CA19-9 0.024 0.028 0.019
    >646 U/mL 4.2   8.7   9.8
    ≤646 U/mL 8.5 12.2 13.6
Post-CRT CA19-9 0.019 0.018 0.038
    >144 U/mL 4.2   8.7   9.8
    ≤144 U/mL 8.6 12.2 13.6
CA19-9 decline 0.212 0.305 0.109
    >87.7% 6.2 10.9 13.2
    ≤87.7% 2.9   8.7   8.7
Disease control status 0.000 0.000 0.000
    Progression 8.5 13.0 13.6
    No progression 2.8   6.4   7.8
PFS, progression-free survival; LRPFS, locoregional progression-free survival; OS, overall survival; DM, diabetes mellitus; ECOG, Eastern Cooperative 
Oncology Group; LN, lymph node; SUVmax, maximum standardized uptake value; MTV, metabolic tumor volume; TLG, total lesion glycolysis; CRT, chemo-
radiation therapy.
*Median survival time is expressed in months.
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more accurately reflect the metabolic tumor burden and pre-
dict survival outcomes when compared to SUVmax, which 
is a single-voxel value.17-19,24
Previous studies on prognostic significance of volumetric 
parameters of PET/CT used simple fixed SUV threshold, 
percentage threshold of SUVmax, or SUV of the liver or 
mediastinal blood pool; however, there is still no consensus 
or standardization on defining the threshold for metabolic 
tumor volume delineation.25,26 We used a fixed SUV thresh-
old of 2.5 and demonstrated that MTV and TLG had prog-
nostic significances. The choice of a fixed SUV threshold 
of 2.5 was largely based on early studies demonstrating that 
an SUV within this range is optimal for differentiating be-
nign lesions from malignant lesions and minimizes inclu-
sion of unwanted physiological FDG uptake in normal tis-
sues.26-29 One recent study using a phantom demonstrated 
that an SUV of 40‒50% of the maximum was appropriate 
for the contouring of actual tumor volume;30 however, we 
could not clearly delineate the primary tumor from sur-
rounding normal structures when 40‒50% of the SUVmax 
of the tumor was applied to a threshold in several cases. In 
addition, it is noteworthy that suggested cutoff values to 
identify a favorable prognostic group vary widely by tumor 
site and study group. Therefore, further studies should fo-
cus on both standardization of threshold SUV and individu-
alization of cutoff values in order to eventually integrate 
volumetric analysis of FDG PET/CT into clinical practices.
CRT has been regarded as a reasonable treatment option 
for LAPC, although the role of radiation therapy remains 
highly controversial. As LAPC is associated with a high 
rate of distant metastases and subsequent poor OS, it is now 
sessed before treatment. Nevertheless, we believe that our 
study has reinforced the prognostic value of CA19-9 levels.
Several recent studies have investigated the prognostic 
value of FDG PET/CT results in patients with pancreatic 
cancer. Despite an absence of standardized cutoff values, 
poorer survival has consistently been associated with high 
SUVmax values measured on pretreatment FDG PET/CT 
scans of patients with primary pancreatic cancer.13-16 How-
ever, to the best of our knowledge, only one other study has 
evaluated the use of FDG PET/CT volumetric parameters 
for predicting clinical outcomes in patients with LAPC. In 
that study, Parlak, et al.20 used the GTV measured during ra-
diotherapy planning as a metabolic parameter measured on 
FDG PET/CT scans of 30 patients with LAPC and showed 
that those with a GTV of <100.0 cm3 had significantly lon-
ger OS and PFS than those with a GTV of >100 cm3. GTV 
is typically used as a parameter for radiotherapy, and MTV 
and TLG are corresponding FDG PET/CT volumetric pa-
rameters used for survival analysis.17-19 In this study, we eval-
uated the prognostic value of MTV and TLG measured on 
pretreatment FDG PET/CT scans of patients with LAPC 
who underwent CRT. Although TLG failed to remain statisti-
cally significant for predicting PFS by multivariate analysis, 
the results of our study demonstrated that MTV and TLG 
were independent prognostic factors and had a stronger as-
sociation with survival outcomes compared to SUVmax. 
MTV is defined as the volume of tumor tissue that shows 
increased FDG uptake over a certain threshold, which in 
our study was an SUV of 2.5, and TLG is representative of 
the metabolic activity throughout the entire tumor. There-
fore, volumetric parameters such as MTV and TLG can 
Table 4. Multivariate Analysis of Prognostic Factors for Survival Outcomes–Metabolic Tumor Volume Model
Variables
PFS LRPFS OS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Pre-CRT CA19-9 2.09 (1.15–3.82) 0.016 1.88 (1.04–3.41) 0.038 1.80 (1.01–3.21) 0.047
SUVmax 1.54 (0.84–2.84) 0.165 1.37 (0.75–2.51) 0.310 1.04 (0.57–1.89) 0.896
MTV 2.21 (1.11–4.41) 0.024 2.33 (1.12–4.83) 0.023 2.12 (1.04–4.30) 0.038
PFS, progression-free survival; LRPFS, locoregional progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SUVmax, maxi-
mum standardized uptake value; MTV, metabolic tumor volume; CRT, chemoradiation therapy.
Table 5. Multivariate Analysis of Prognostic Factors for Survival Outcomes –Total Lesion Glycolysis Model
Variables
PFS LRPFS OS
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Pre-CRT CA19-9 2.21 (1.22–3.98) 0.009 2.24 (1.23–4.08) 0.008 2.14 (1.20–3.84) 0.010 
SUVmax 1.69 (0.87–3.27) 0.122 1.26 (0.68–2.34) 0.466 0.94 (0.50–1.76) 0.838 
TLG 1.56 (0.82–2.98) 0.178 2.41 (1.26–4.61) 0.008 2.19 (1.14–4.21) 0.019
PFS, progression-free survival; LRPFS, locoregional progression-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval; SUVmax, maxi-
mum standardized uptake value; TLG, total lesion glycolysis; CRT, chemoradiation therapy.
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cancer lesion, mainly due to obstructive pancreatitis. In 
those patients, it was difficult to clearly differentiate tumor 
uptake from inflammatory uptake due to pancreatitis, which 
may have affected the measurement of MTV. We theorize 
that simultaneous anatomic correlation with other imaging 
modalities, such as PET-contrast-enhanced CT or PET-
magnetic resonance imaging (PET/MRI) would be one so-
lution to this problem. Third, use of different PET/CT scan-
ners may have contributed to SUV variability to a certain 
extent and biased the results of the present study, although 
the variations of SUV among PET/CT systems in our insti-
tute were within the acceptable limit.35
In conclusion, MTV measured on pretreatment FDG PET/
CT scans was an independent and significant prognostic fac-
tor for predicting the PFS, LRPFS, and OS, as was TLG for 
predicting the LRPFS and OS, in patients with LAPC treated 
with gemcitabine-based CRT. FDG PET/CT volumetric pa-
rameters might have the potential to identify the subgroup of 
patients who would benefit from RT as a part of CRT.
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